- Home
- ZYME vs BY Comparison
ZYME vs BY Comparison
Compare ZYME & BY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- BY
- Stock Information
- Founded
- ZYME 2003
- BY 1914
- Country
- ZYME United States
- BY United States
- Employees
- ZYME N/A
- BY 1027
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- BY Major Banks
- Sector
- ZYME Health Care
- BY Finance
- Exchange
- ZYME Nasdaq
- BY Nasdaq
- Market Cap
- ZYME 1.2B
- BY 1.2B
- IPO Year
- ZYME 2017
- BY 2017
- Fundamental
- Price
- ZYME $18.04
- BY $26.98
- Analyst Decision
- ZYME Strong Buy
- BY Hold
- Analyst Count
- ZYME 8
- BY 3
- Target Price
- ZYME $24.00
- BY $33.00
- AVG Volume (30 Days)
- ZYME 668.9K
- BY 182.1K
- Earning Date
- ZYME 11-06-2025
- BY 10-23-2025
- Dividend Yield
- ZYME N/A
- BY 1.53%
- EPS Growth
- ZYME N/A
- BY N/A
- EPS
- ZYME N/A
- BY 2.68
- Revenue
- ZYME $122,867,000.00
- BY $384,591,000.00
- Revenue This Year
- ZYME $107.76
- BY $18.69
- Revenue Next Year
- ZYME $2.35
- BY $3.10
- P/E Ratio
- ZYME N/A
- BY $9.78
- Revenue Growth
- ZYME 95.94
- BY 2.48
- 52 Week Low
- ZYME $9.03
- BY $22.63
- 52 Week High
- ZYME $19.50
- BY $32.89
- Technical
- Relative Strength Index (RSI)
- ZYME 65.50
- BY 46.19
- Support Level
- ZYME $18.21
- BY $25.57
- Resistance Level
- ZYME $19.10
- BY $27.68
- Average True Range (ATR)
- ZYME 0.69
- BY 0.69
- MACD
- ZYME 0.02
- BY -0.08
- Stochastic Oscillator
- ZYME 56.97
- BY 50.53
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About BY Byline Bancorp Inc.
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.